Cell-type specific differences in glutamate cysteine ligase transcriptional regulation demonstrate independent subunit control.
Glutamate cysteine ligase (GCL; also referred to as gamma-glutamylcysteine synthetase, GCS) catalyzes the rate-limiting step of glutathione synthesis. The GCL holoenzyme is composed of a catalytic (GCLC; also called GCS(h)) and a modifier (GCLM; also called GCS(l)) subunit, each encoded by a unique gene. Wild-type and mutant promoter/luciferase reporter transgenes containing the promoter region of each GCL subunit gene were transfected into A549 (lung carcinoma), HEK 293 (transformed embryonic kidney), HepG2 (hepatocellular carcinoma), and RD (skeletal muscle rhabdomyosarcoma) cells to examine potential cell-type related differences in transcriptional regulation. In A549, HepG2, and RD cells, maximal basal expression of the GCLC transgene required the full-length (-3802 bp) promoter. Maximal expression in HEK 293 cells was uniquely directed by cis-elements contained within the -2752 to -1286 bp fragment of the promoter. No differences in GLCM promoter function were detected among these 4 cell lines. GCL subunit induction in each cell line by pyrrolidine dithiocarbamate (PDTC), phenethyl isothiocyanate (PEITC), and beta-naphthoflavone (beta-NF) was examined by RNAse protection assays. Although both genes were similarly induced in HepG2 cells by beta-NF, PDTC, and PEITC, neither was induced by beta-NF in A549, HEK 293, and RD cells. PDTC and PEITC induced GCLM to a much greater extent than GCLC in HEK 293 cells and failed to induce GCLC in RD cells. Neither subunit was induced by any of the agents in A549 cells. These studies indicate that the GCL subunit genes are independently regulated and display cell-type specific differences in both basal and inducible expression.
Dahl
E L
EL
Environmental Toxicology Center and Department of Pharmacology, University of Wisconsin, Madison, Wisconsin 53792, USA.
Mulcahy
R T
RT
D002460:Cell Line; D002461:Cell Line, Transformed; D015342:DNA Probes / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D017930:Genes, Reporter / Q000235:genetics; D005721:Glutamate-Cysteine Ligase / Q000235:genetics*; D006801:Humans; D017879:Isothiocyanates / Q000494:pharmacology; D007668:Kidney / Q000201:enzymology; D008156:Luciferases / Q000235:genetics; D009928:Organ Specificity; D011401:Promoter Regions, Genetic; D011759:Pyrrolidines / Q000494:pharmacology; D012313:RNA / Q000302:isolation & purification; D012333:RNA, Messenger / Q000235:genetics; D013859:Thiocarbamates / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured; D019324:beta-Naphthoflavone / Q000494:pharmacology
D015342:DNA Probes; D017879:Isothiocyanates; D011759:Pyrrolidines; D012333:RNA, Messenger; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D019324:beta-Naphthoflavone; D012313:RNA; C058305:phenethyl isothiocyanate; D008156:Luciferases; D005721:Glutamate-Cysteine Ligase